HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Gerald S. Weinstein Denis H. Tyras Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weinstein, G. S. Articles by Tyras, D. H. Search for Related Content PubMed PubMed Citation Articles by Weinstein, G. S. Articles by Tyras, D. H.

Ann Thorac Surg 1990;49:419-423
© 1990 The Society of Thoracic Surgeons

---

Articles

Reduction of myocardial injury with verapamil before aortic cross-clamping

Long Island Jewish Medical Center, New Hyde Park, New York USA

Accepted for publication November 1, 1989.

^_* Address reprint requests to Dr Weinstein, Division of Cardiothoracic Surgery, Long Island Jewish Medical Center, New Hyde Park, NY 11042.

The effect of verapamil administered before aortic crossclamping was assessed in 40 patients undergoing elective coronary artery bypass grafting. Myocardial protection consisted of cold blood potassium cardioplegia, topical ice slush, and moderate (28 °C) systemic hypothermia. Patients were randomly divided into two groups: group 1 (18 patients) received verapamil (0.1 mg/kg up to 10 mg) intravenously three to five minutes before aortic crossclamping; group 2 (22 patients) did not (control). Myocardial injury was assessed by cumulative release of the cardiac-specific noenzyme of creatine kinase (CK-MB) after release of the aortic cross-clamp. Release of CK-MB was significantly lower in the verapamil group (44.9 ± 6.2 versus 72.2 ± 9.0 IU at 24.5 hours, p = 0.005). Calculated total infarct size was also lower in the verapamil group (6.0 ± 0.9 versus 8.9 ± 1.0 g-Eq, p = 0.035). Individual CK-MB release curves showed either one or two peaks. The two-peak pattern was more frequent in control patients (18 of 21 control patients versus 6 of 18 verapamil patients, p = 0.001) and was associated with a larger infarct size. Atrioventricular pacing was not required in any verapamil patient, but was needed in 1 control patient. We conclude that verapamil administered before aortic cross-clamping protects against myocardial injury during coronary artery bypass grafting with no increase in the incidence of atrioventricular block.

This article has been cited by other articles:

				U. Acikel, E. Hazan, N. Sariosmanoglu, H. Catalyurek, E. Silistreli, G. Guner, N. Saydam, Y. Tuncok, H. Guven, O. Karabay, et al. Nisoldipine Cardioplegia in the Isolated Rabbit Heart Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 285 - 290. [Abstract] [PDF]

				H. B. Barner Blood cardioplegia: A review and comparison with crystalloid cardioplegia Ann. Thorac. Surg., December 1, 1991; 52(6): 1354 - 1367. [Abstract] [PDF]

				P. S. Brown, G. L. Parenteau, F. W. Holland, and R. E. Clark Pretreatment with nicardipine preserves ventricular function after hypothermic ischemic arrest Ann. Thorac. Surg., May 1, 1991; 51(5): 739 - 746. [Abstract] [PDF]